HK1180683A1 - 抗感染化合物 - Google Patents

抗感染化合物

Info

Publication number
HK1180683A1
HK1180683A1 HK13108001.5A HK13108001A HK1180683A1 HK 1180683 A1 HK1180683 A1 HK 1180683A1 HK 13108001 A HK13108001 A HK 13108001A HK 1180683 A1 HK1180683 A1 HK 1180683A1
Authority
HK
Hong Kong
Prior art keywords
infective compounds
infective
compounds
Prior art date
Application number
HK13108001.5A
Other languages
English (en)
Inventor
Zaesung No
Jaeseung Kim
Priscille Brodin Brodin
Min Jung Seo
Young Mi Kim
Jonathan Cechetto
Heekyoung Jeon
Auguste Genovesio
Saeyeon Lee
Sunhee Kang
Fanny Anne Ewann
Ji Youn Nam
Thierry Christophe
Denis Philippe Cedric Fenistein
Heo Jamung
Jang Jiyeon
Original Assignee
Pasteur Institut Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut Korea filed Critical Pasteur Institut Korea
Publication of HK1180683A1 publication Critical patent/HK1180683A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
HK13108001.5A 2010-03-18 2013-07-09 抗感染化合物 HK1180683A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31511310P 2010-03-18 2010-03-18
US201161440937P 2011-02-09 2011-02-09
PCT/EP2011/001345 WO2011113606A1 (en) 2010-03-18 2011-03-18 Anti-infective compounds

Publications (1)

Publication Number Publication Date
HK1180683A1 true HK1180683A1 (zh) 2013-10-25

Family

ID=44021876

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13108001.5A HK1180683A1 (zh) 2010-03-18 2013-07-09 抗感染化合物

Country Status (18)

Country Link
US (1) US8865734B2 (zh)
EP (1) EP2547678B1 (zh)
JP (1) JP5944837B2 (zh)
KR (1) KR101732212B1 (zh)
CN (1) CN102869661B (zh)
AU (1) AU2011229423B2 (zh)
BR (1) BR112012023576B1 (zh)
CA (1) CA2793086C (zh)
ES (1) ES2572387T3 (zh)
HK (1) HK1180683A1 (zh)
IL (1) IL221940A (zh)
MX (1) MX345762B (zh)
NZ (1) NZ602311A (zh)
PL (1) PL2547678T3 (zh)
RU (1) RU2576662C2 (zh)
SG (2) SG10201502109VA (zh)
WO (1) WO2011113606A1 (zh)
ZA (1) ZA201206814B (zh)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106866667B (zh) * 2009-11-05 2019-11-15 圣母大学 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US9365574B2 (en) 2010-05-27 2016-06-14 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2012045729A1 (en) * 2010-10-05 2012-04-12 Glaxo Group Limited Imidazo [1, 2 -a] pyridine and pyrazolo [1, 5 -a] pyridine derivatives as trpv1 antagonists
KR102104125B1 (ko) * 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
MX2013014082A (es) 2011-05-30 2014-03-21 Astellas Pharma Inc Compuestos de imidazopiridina.
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US20150126530A1 (en) * 2011-10-21 2015-05-07 Torrent Pharmaceuticals Limited Novel Substituted Imidazopyrimidines as Gpbar1 Receptor Modulators
US8765959B2 (en) * 2011-12-23 2014-07-01 Boehringer Ingelheim International Gmbh Piperidine derivatives
WO2014015167A2 (en) * 2012-07-18 2014-01-23 University Of Notre Dame Du Lac 5,5-heteroaromatic anti-infective compounds
WO2014021383A1 (ja) * 2012-07-31 2014-02-06 協和発酵キリン株式会社 縮環複素環化合物
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8778964B2 (en) 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
US8796305B2 (en) 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9624214B2 (en) * 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
MX2015006856A (es) * 2012-11-30 2016-02-17 Astellas Pharma Inc Compuestos imidazopiridina.
PL3808749T3 (pl) 2012-12-07 2023-07-10 Vertex Pharmaceuticals Incorporated Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2014195333A1 (de) 2013-06-04 2014-12-11 Bayer Pharma Aktiengesellschaft 3-aryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung
WO2015009525A1 (en) * 2013-07-17 2015-01-22 Global Alliance For Tb Drug Development Azaindole compounds, synthesis thereof, and methods of using the same
EP3027615B1 (en) * 2013-08-02 2021-07-21 Institut Pasteur Korea Anti-infective compounds
JP6543252B2 (ja) 2013-12-06 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ＡＴＲキナーゼ阻害剤として有用な２−アミノ−６−フルオロ−Ｎ−［５−フルオロ−ピリジン−３−イル］ピラゾロ［１，５−ａ］ピリミジン−３−カルボキサミド化合物、その調製、その異なる固体形態および放射性標識された誘導体
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
ES2672797T3 (es) 2014-02-13 2018-06-18 Incyte Corporation Ciclopropilaminas como inhibidores de LSD1
CA2939082C (en) 2014-02-13 2022-06-07 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
ME03580B (me) 2014-02-13 2020-07-20 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
CA2939793A1 (en) 2014-02-19 2015-08-27 Bayer Pharma Aktiengesellschaft 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
WO2015140199A1 (de) 2014-03-21 2015-09-24 Bayer Pharma Aktiengesellschaft Cyano-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
US20170057958A1 (en) 2014-05-02 2017-03-02 Bayer Pharma Aktiengesellschaft Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseases
CN103965193B (zh) * 2014-05-30 2016-04-06 浙江司太立制药股份有限公司 N-(苯氧烷基)咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法
MX2016015874A (es) 2014-06-05 2017-03-27 Vertex Pharma Derivados radiomarcadores de un compuesto de 2-amino-6-fluoro-n-[5 -fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
PT3157566T (pt) 2014-06-17 2019-07-11 Vertex Pharma Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
JP2017536396A (ja) 2014-12-02 2017-12-07 バイエル・ファルマ・アクティエンゲゼルシャフト ヘテロアリール置換イミダゾ［１，２−ａ］ピリジンおよびその使用
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
MD3316969T2 (ro) * 2015-07-02 2022-07-31 Janssen Sciences Ireland Unlimited Co Compuși antibacterieni
CR20180152A (es) 2015-08-12 2018-08-09 Incyte Corp Sales de un inhibidor de lsd1
CA2998375A1 (en) * 2015-09-17 2017-03-23 Marvin J. Miller Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
CA3000684A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
EP3386993A1 (de) 2015-12-10 2018-10-17 Bayer Pharma Aktiengesellschaft Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung
GEP20207104B (en) 2015-12-10 2020-05-11 Bayer Pharma AG 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
SG11201805300QA (en) 2015-12-22 2018-07-30 Incyte Corp Heterocyclic compounds as immunomodulators
CN108884044B (zh) * 2016-02-26 2023-01-31 大塚制药株式会社 哌啶衍生物
MX2018012901A (es) 2016-04-22 2019-06-06 Incyte Corp Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3025727A1 (en) 2016-06-16 2017-12-21 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
US11179396B2 (en) * 2016-06-16 2021-11-23 Janssen Sciences Ireland Uc Heterocyclic compounds as antibacterials
CA3028685A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
JOP20190005A1 (ar) 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
CN106279123B (zh) * 2016-08-15 2018-09-04 郑州大学 3-(苯磺酰甲基)咪唑并杂环类化合物及其合成方法
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
HRP20221216T1 (hr) 2016-12-22 2022-12-23 Incyte Corporation Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
ES2934230T3 (es) 2016-12-22 2023-02-20 Incyte Corp Derivados de benzooxazol como inmunomoduladores
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
EA201991997A1 (ru) 2017-03-01 2020-01-22 Янссен Сайенсиз Айрлэнд Анлимитед Компани Комбинированная терапия
WO2018184976A1 (de) 2017-04-05 2018-10-11 Bayer Pharma Aktiengesellschaft Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
EP3428815A1 (en) 2017-07-11 2019-01-16 Institut Pasteur Docking method based on saturation transfer difference nmr data, and means for its implementation
US11129816B2 (en) 2017-10-05 2021-09-28 Quretech Bio Ab Ring-fused thiazolino 2-pyridones in combination with a drug against tuberculosis
AU2018380132B2 (en) 2017-12-06 2023-11-09 Lin Bioscience, Inc. Tubulin inhibitors
CN108159049B (zh) * 2018-02-01 2021-01-05 中国科学院广州生物医药与健康研究院 一种吡啶类化合物的新用途
EP3746422A4 (en) * 2018-02-01 2021-06-09 The University Of Sydney ANTI-CANCER COMPOUNDS
EP3759109B1 (en) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
CN112384515A (zh) 2018-02-27 2021-02-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
FI3774791T3 (fi) 2018-03-30 2023-03-21 Incyte Corp Heterosyklisiä yhdisteitä immunomodulaattoreina
CN112752756A (zh) 2018-05-11 2021-05-04 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
EP3818063A1 (en) 2018-07-05 2021-05-12 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN109651363B (zh) * 2019-01-03 2020-06-26 东华理工大学 胺甲基化咪唑并[1,2-a]吡啶化合物及制备方法
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN114206445A (zh) * 2019-07-30 2022-03-18 奎利恩特有限公司 6-氯-2-乙基-N-(4-(4-(4-(三氟甲氧基)苯基)哌啶-1-基)苯甲基)咪唑并[1，2-a]吡啶-3-甲酰胺的不同形式
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
TW202124379A (zh) * 2019-09-10 2021-07-01 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的５，６－雜芳族化合物
WO2021048342A1 (en) 2019-09-13 2021-03-18 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
AU2020357514A1 (en) 2019-09-30 2022-04-07 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
JP2022551823A (ja) 2019-09-30 2022-12-14 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌化合物
KR20220071199A (ko) * 2019-09-30 2022-05-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 4-퀴놀리논 항균 화합물
WO2021096849A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
WO2021122996A1 (en) * 2019-12-20 2021-06-24 Qurient Co., Ltd. A pharmaceutical oral dosage form of q203
CA3174992A1 (en) * 2020-03-02 2021-09-10 Sironax Ltd. Ferroptosis inhibitors - diarylamine para-acetamides
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
CN111393435A (zh) * 2020-03-16 2020-07-10 青岛吉澳医药科技有限公司 氮杂吲哚酰胺类化合物及其制备方法和用途
EP4181921A1 (en) 2020-07-15 2023-05-24 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11744823B2 (en) 2020-11-19 2023-09-05 Third Harmonic Bio, Inc. Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
WO2022119899A1 (en) * 2020-12-02 2022-06-09 Shionogi & Co., Ltd. A medicament for treating mycobacterial infection characterized by combining a cytochrome bc1 inhibitor with clarithromycin or azithromycin
BR112023018662A2 (pt) 2021-03-16 2023-12-19 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
CN117580843A (zh) 2021-03-17 2024-02-20 爱尔兰詹森科学公司 抗菌化合物
AU2022236404A1 (en) 2021-03-17 2023-11-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
TW202325274A (zh) 2021-10-28 2023-07-01 愛爾蘭商健生科學愛爾蘭無限公司 抗菌化合物
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE598759A (zh) * 1960-01-04
US3133076A (en) * 1961-04-06 1964-05-12 Simes Phenyl-imidazo(1, 2-a)pyridine-6-car-boxylic acids and their esters
US3105834A (en) * 1961-10-11 1963-10-01 Norwich Pharma Co 2-(5-nitro-2-furyl)-imidazo [1, 2-alpha]-pyridine or-pyrimidine
US6080767A (en) * 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
CA2386813C (en) * 1999-10-08 2008-09-02 Grunenthal Gmbh Bicyclic imidazo-3-yl amine derivatives substituted on the 6-membered ring
WO2001092257A1 (en) * 2000-05-26 2001-12-06 Neurogen Corporation Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands
JP2007529496A (ja) * 2004-03-19 2007-10-25 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌剤としてのイミダゾピリジン及びイミダゾピリミジン誘導体
WO2007027999A2 (en) * 2005-08-31 2007-03-08 Smithkline Beecham Corporation Chemical compounds
WO2007034282A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
WO2007034278A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Fused imidazole derivatives as c3a receptor antagonists
WO2008082490A2 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
CL2008001631A1 (es) * 2007-06-06 2009-01-02 Smithkline Beecham Corp Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih.
US8148380B2 (en) 2007-07-23 2012-04-03 Crestone, Inc. Antibacterial amide and sulfonamide substituted heterocyclic urea compounds
CA2727651C (en) 2008-06-17 2016-04-05 Priscille Brodin Anti-infective compounds
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
CN106866667B (zh) * 2009-11-05 2019-11-15 圣母大学 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法

Also Published As

Publication number Publication date
WO2011113606A1 (en) 2011-09-22
RU2576662C2 (ru) 2016-03-10
MX2012010671A (es) 2013-04-03
CN102869661A (zh) 2013-01-09
AU2011229423B2 (en) 2015-12-10
CA2793086A1 (en) 2011-09-22
IL221940A (en) 2017-03-30
WO2011113606A8 (en) 2012-10-26
ZA201206814B (en) 2016-03-30
BR112012023576B1 (pt) 2022-08-23
SG184073A1 (en) 2012-10-30
KR101732212B1 (ko) 2017-05-02
AU2011229423A1 (en) 2012-09-27
PL2547678T3 (pl) 2016-10-31
RU2012144317A (ru) 2014-04-27
NZ602311A (en) 2014-08-29
CN102869661B (zh) 2015-08-05
KR20130028723A (ko) 2013-03-19
CA2793086C (en) 2018-08-21
ES2572387T3 (es) 2016-05-31
EP2547678B1 (en) 2016-03-16
JP2013522253A (ja) 2013-06-13
EP2547678A1 (en) 2013-01-23
US8865734B2 (en) 2014-10-21
MX345762B (es) 2017-02-15
JP5944837B2 (ja) 2016-07-05
US20130065884A1 (en) 2013-03-14
SG10201502109VA (en) 2015-05-28
BR112012023576A2 (pt) 2020-09-01

Similar Documents

Publication Publication Date Title
HK1180683A1 (zh) 抗感染化合物
IL223783A0 (en) Pro-neurogenic compounds
GB201008134D0 (en) Compounds
GB201015949D0 (en) Compounds
HK1187908A1 (zh) 咪唑並三嗪酮化合物
GB201020179D0 (en) New compounds
GB201007286D0 (en) New compounds
AP2012006641A0 (en) New compounds
GB201007347D0 (en) Compounds
EP2605658A4 (en) SPIROXAZOLIDINONVERBINDUNGEN
EP2649050A4 (en) LINKS
GB201002563D0 (en) Compounds
GB201008209D0 (en) Compounds
GB201001688D0 (en) Compounds
GB201002911D0 (en) Compound
GB201002216D0 (en) Compounds
GB201015537D0 (en) Compounds
GB201008210D0 (en) Compounds
GB201001796D0 (en) Compounds
GB201021494D0 (en) Compounds
GB201007209D0 (en) Compound
GB201022042D0 (en) Compounds
GB201019227D0 (en) Compounds
GB201015757D0 (en) Compounds
GB201015145D0 (en) Compounds